The management of asymptomatic carotid stenosis has drifted towards intensive medical therapy alone as that therapy has improved. A commentary in Neurology revisits this in light of CREST-2.

According to the commentary, CREST-2 showed that carotid artery stenting added to intensive medical management significantly reduced stroke risk in patients with high-grade asymptomatic stenosis, compared with medical management alone. The author frames stenting as an evidence-based adjunct rather than a competitor to medical therapy, and stresses that careful patient selection and operator skill are decisive, with shared decision-making central.

The practical implication is to keep stenting on the table for selected patients with high-grade asymptomatic stenosis, as an addition to optimised medical therapy, rather than treating medical therapy as automatically sufficient for everyone. The full trial report and individual risk should drive the conversation.

A Neurology commentary interprets CREST-2 for asymptomatic carotid stenosis.
CREST-2 is described as showing stenting plus medical management cut stroke versus medical management alone.
Stenting is framed as an adjunct to intensive medical therapy, not a replacement.
Patient selection and operator skill are presented as decisive to benefit.
Use shared decision-making for high-grade asymptomatic stenosis.

Why it matters

It pushes back on the drift towards medical therapy alone for all asymptomatic carotid stenosis.

Don't overread it

This is a commentary rather than the primary trial report; patient selection and operator skill determine whether the trial benefit is reproduced in practice.